Gilead Sciences Inc (GILD) FY2025Q2 Earning Prediction

08/07 04:00:00

After Hours

Gilead Sciences Inc (GILD) is set to release its FY2025Q2 earnings performance on 08/07 04:00:00 in After Hours trading. Consensus forecasts predict a revenue of 6.96B and an earnings per share (EPS) of 1.95 for the FY2025Q2. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!

Estimate

Actual

Surprise

RevenueBEAT

6.96B

7.08B

+1.69%

EPSBEAT

1.95

2.01

+3.08%

AI Earnings Prediction

Prediction for FY2025Q2

Earnings Date: Aug 7, 2025

The earnings forecast suggests a neutral outcome due to limited immediate impact from new product launches and increased expenses.

Neutral

Last 0 quarters:

4 beats1 misses

Scenario Analysis

The AI analyzes the probability of each scenario occurring and identifies the triggering conditions.

Scenario

Prob.

Stock Reaction

Trigger Condition

Strong Beat

10%

+5–7%

Faster-than-expected Yeztugo adoption + surprise cost controls.

Beat

20%

+2–4%

HIV sales modestly beat + lower SG&A.

Neutral

50%

Flat

In-line results with Yeztugo progress noted but no near-term EPS upside.

Miss

15%

-3–5%

Larger-than-expected Veklury decline + expense leakage.

Strong Miss

-8–10%

HIV sales soften + pipeline setbacks (e.g., anito-cel delays).

Unlock Free Scenario Probability

Key Indicators Forecast

The AI provides itemized forecasts for key indicators, potentially including revenue, EPS, gross margin, and free cash flow.

Revenue

EPS

Currency:

No data

Actual

Estimate

Metric

Prediction

Justification

Revenue

Neutral

Yeztugo approval timing limits Q2 contribution; steady HIV/liver growth offsets Veklury decline.

EPS

Miss

Acquired IPR&D expenses ($61M) and Kymera deal costs ($0.02–$0.03/share) pressure earnings.

Unlock Free Key Indicators Forecast

Prediction Logic & Rational

Logic & Justification

Key Factors from Fact Data:

HIV Franchise Momentum vs. Timing of Yeztugo Impact

Yeztugo (lenacapavir) received FDA approval on June 18, 2025, for HIV prevention, but its commercial launch and revenue contribution in Q2 (ending June 30) are likely nascent. Analysts expect a "slow and steady" ramp due to access challenges and potential cannibalization of Descovy.
The Supreme Court’s upholding of preventive services coverage (including PrEP) removes regulatory uncertainty but does not materially accelerate near-term sales.

Expenses Pressuring EPS

Gilead guided for a $ 0.04/share hit from $61M in acquired IPR&D expenses (including $40M from Kymera partnership) and lowered FY25 EPS guidance by $ 0.02–$ 0.03 due to upfront collaboration costs.
These expenses are non-recurring but directly impact Q2 EPS.

Veklury Decline Partially Offset by Core HIV/Liver Growth

Veklury sales are expected to decline further (consistent with consensus), but base HIV (Biktarvy/Descovy) and liver disease drugs (Livdelzi) show stable growth. No material upside surprises here.

Mixed Pipeline Updates

Positive data for Trodelvy in breast cancer and anito-cel (CAR-T) updates are promising but unlikely to materially impact Q2 revenue.
Clinical holds on GS-1720/4182 (HIV treatment) are a minor headwind but unrelated to core revenue drivers.

Prediction Logic & Rational

Tactical Strategy Recommendations

Trading Strategy

Short-Term Play (Pre-Earnings):
- Short Strangle (Sell ATM Calls/Puts): Neutral outlook suggests muted volatility; capitalize on inflated options premiums.
- Hedge with Long Puts: Protect against downside from EPS miss (expense-driven).
Long-Term Play:
- Buy on Weakness Post-Earnings: Yeztugo’s multi-year growth potential and anito-cel updates (H2 2025) remain undervalued if Q2 results dip the stock.
  Rationale: The market has priced in Yeztugo’s approval but remains cautious on near-term execution. Neutral earnings with a focus on pipeline progress (e.g., anito-cel, Trodelvy) sets up better entry points post-Q2.

Tactical Strategy Recommendations

Earnings Surprise Analysis

The chart displays the extent of earnings surprises and corresponding stock price movements for each earnings event.

Revenue

EPS

GILD Transcript

Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript

Neutral12-3

Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Neutral12-3

Gilead Sciences, Inc. (GILD) Presents at Jefferies London Healthcare Conference 2025 Transcript

Neutral11-19

Gilead Sciences, Inc. (GILD) Presents at UBS Global Healthcare Conference 2025 Transcript

Neutral11-10

GILD Slides

Gilead Q225 slides: HIV strength drives guidance raise, oncology pipeline advances

2025-08-07

Gilead Q3 2025 slides: HIV strength drives guidance raise, new products gain traction

2025-10-30

GILD Report

GILEAD SCIENCES, INC. 10-Q

10-Q

2024-11-12

GILEAD SCIENCES, INC. 10-Q

10-Q

2024-05-08

GILEAD SCIENCES, INC. 10-K

10-K

2024-02-23

GILEAD SCIENCES, INC. 10-Q

10-Q

2023-11-07

Frequently Asked Questions

What is the Gilead Sciences Inc FY2025Q2 Earnings Release Date and Time?

Gilead Sciences Inc (GILD) is scheduled to release its FY2025Q2 earnings report onAug 7, 2025, After Hours(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.

What Are the Consensus Forecasts for Gilead Sciences Inc FY2025Q2 Revenue and EPS?

Analysts' consensus predicts 6.96B in revenue and an EPS of 1.95 for Gilead Sciences Inc's FY2025Q2.

What Does Intellectia's AI Predict for Gilead Sciences Inc FY2025Q2 Earnings?

Intellectia's exclusive AI algorithms forecast a Neutral forGilead Sciences Inc's FY2025Q2 earnings, with a prediction date of Aug 7, 2025. Gilead Sciences Inc The earnings forecast suggests a neutral outcome due to limited immediate impact from new product launches and increased expenses.

How Can I Use This Earnings Prediction to Trade GILD Stock?

Leverage Intellectia's AI forecast to position trades ahead of theAug 7, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.

How Accurate Is Intellectia's AI for Earnings Predictions Like Gilead Sciences Inc FY2025Q2?

Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.

How does AI Earnings Prediction generate its forecasts?

AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!

When are the predictions available, and how often are they updated?

Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.

Can I use AI Earnings Prediction for all types of stocks?

Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!